Screening for prostate cancer: current recommendations (Q35763071)

10 August 2017

1 reference

title

Screening for prostate cancer: current recommendations (English)

1 reference

10 August 2017

1 reference

Shandra S Wilson

1

1 reference

10 August 2017

E David Crawford

series ordinal

2

1 reference

10 August 2017

publication date

1 May 2004

1 reference

Urologic Clinics of North America

10 August 2017

published in

1 reference

10 August 2017

volume

31

1 reference

10 August 2017

issue

2

1 reference

10 August 2017

page(s)

219-226

1 reference

10 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Screening for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Positive predictive value of screening mammography by age and family history of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Prostate-specific antigen: current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

The influence of finasteride on the development of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Family history and prostate cancer screening with prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

A prospective study of physical activity and risk of prostate cancer in US physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

The role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Diagnostic potential of serum proteomic patterns in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Changing trends in U.S. prostate cancer incidence rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Patient-re ported complications and follow-up treatment after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Have complication rates decreased after treatment for localized prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Prostate cancer: different incidence but not mortality trends within two areas of Tuscany, Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Comparison of trends in prostate-cancer mortality in England and Wales and the USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Downward trend in prostate cancer mortality in Quebec and Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

International trends in prostate-cancer mortality in the "PSA ERA".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Patient age as a prognostic factor in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Prostatic Carcinoma: Incidence and Location of Unsuspected Lymphatic Metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Population-based study of long-term survival in patients with clinically localised prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

Adenocarcinoma of the prostate: results of routine urological screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Diagnostic Methods in the Detection of Prostate Cancer: A Study of a Randomly Selected Population of 2,400 Men

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2004.01.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UCL.2004.01.002

1 reference

10 August 2017

1 reference